Skip to main content
. 2024 Jun 20;9(9):2648–2656. doi: 10.1016/j.ekir.2024.06.020

Table 6.

Adverse events reported on or after ravulizumab initiation

Adverse event All patients (N = 60), n (%) Events, n
Infection 7 (12) 7
Atrial fibrillation 2 (3) 2
Malignancya 2 (3) 2
Gastroenteritis 1 (2) 2
Fatigue 1 (2) 1
Fever 1 (2) 1
Headache 1 (2) 1
Infusion reaction 1 (2) 1
Seizures 1 (2) 1
Testicular torsion 1 (2) 1
Transient cerebral ischemia 1 (2) 1
a

One event of squamous cell carcinoma and one event of malignant melanoma.